CVKD (Cadrenal Therapeutics) Other Current Receivables: $0.01 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVKD Cadrenal Therapeutics Inc CVKD
26 GF Score
Price $2.03
! 2 Warning Signs
View Full Analysis

What is Cadrenal Therapeutics Other Current Receivables?

Cadrenal Therapeutics CVKD +2.01% 26 Other Current Receivables is $0.01 Mil as of Mar. 2026. GuruFocus rates CVKD with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Cadrenal Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.01 Mil.

Cadrenal Therapeutics's quarterly Other Current Receivables declined from Sep. 2025 ($0.01 Mil) to Dec. 2025 ($0.01 Mil) but then stayed the same from Dec. 2025 ($0.01 Mil) to Mar. 2026 ($0.01 Mil).

Cadrenal Therapeutics's annual Other Current Receivables increased from Dec. 2023 ($0.04 Mil) to Dec. 2024 ($0.04 Mil) but then declined from Dec. 2024 ($0.04 Mil) to Dec. 2025 ($0.01 Mil).

Cadrenal Therapeutics Other Current Receivables Related Terms

Cadrenal Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Cadrenal Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadrenal Therapeutics Other Current Receivables Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Other Current Receivables
0.00 0.04 0.04 0.01

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.02 0.01 0.01 0.01
CVKD
26GF Score
Cadrenal Therapeutics Inc CVKD
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cadrenal Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.01 Mil mean?
Cadrenal Therapeutics (CVKD) has a Other Current Receivables of $0.01 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cadrenal Therapeutics and its competitors.
Is Cadrenal Therapeutics' Other Current Receivables too high?
Cadrenal Therapeutics' current Other Current Receivables is $0.01 Mil. Overall, Cadrenal Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' Other Current Receivables compare to RVPH and IMNN?
Cadrenal Therapeutics' Other Current Receivables of $0.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Cadrenal Therapeutics and its competitors. Cadrenal Therapeutics's current Other Current Receivables is $0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current Other Current Receivables of $0.01 Mil. The current Other Current Receivables is $0.01 Mil. Cadrenal Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current Other Current Receivables is $0.01 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cadrenal Therapeutics Business Description

Address 822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
26GF Score

Get the complete analysis for CVKD

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.03
Price